<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02586168</url>
  </required_header>
  <id_info>
    <org_study_id>1027-014</org_study_id>
    <nct_id>NCT02586168</nct_id>
  </id_info>
  <brief_title>The Effect of Gemcabene on Insulin Sensitivity in Nondiabetic Subjects</brief_title>
  <official_title>The Effect of Gemcabene (CI‐1027) on Insulin Sensitivity in Nondiabetic Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gemphire Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gemphire Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of gemcabene on insulin sensitivity as
      defined by average glucose disposal rate.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2001</start_date>
  <completion_date type="Actual">October 2001</completion_date>
  <primary_completion_date type="Actual">October 2001</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG</measure>
    <time_frame>4 weeks</time_frame>
    <description>Clinically Significant Changes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Laboratory - hematology, chemistry</measure>
    <time_frame>4 weeks</time_frame>
    <description>Clinical Laboratory Abnormalities</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Insulin Sensitivity</condition>
  <arm_group>
    <arm_group_label>Gemcabene 900 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcabene 900 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcabene 900 mg</intervention_name>
    <description>Gemcabene 900 mg once daily (QD)</description>
    <arm_group_label>Gemcabene 900 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Good health, as determined by medical history, physical examination, EKG and clinical
             laboratory assessments

          -  Males; and females of non‐reproductive potential

          -  Obesity

          -  Non‐diabetic

        Exclusion Criteria:

          -  Use of any medication considered unacceptable by the clinical investigators during the
             14‐day period before the start of Day 1. Hormone Replacement Therapy is acceptable.

          -  Use of a lipid‐lowering agent (niacin, fibrates, statin) during the 8 weeks before
             screening

          -  Use of any anti‐diabetic medications

          -  Use of any steroid medications

          -  Donation of any blood or plasma product or participation in another study in the 30
             days prior to Day 1

          -  If female, pregnant, lactating or of childbearing potential; and

          -  History of significant reaction to any fibrate lipid‐lowering agent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2015</study_first_submitted>
  <study_first_submitted_qc>October 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2015</study_first_posted>
  <last_update_submitted>October 22, 2015</last_update_submitted>
  <last_update_submitted_qc>October 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Insulin Resistance</keyword>
  <keyword>Lipid Regulator</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

